Premium Nahrungsergänzungsmittel | artgerecht

Niemann-Pick-C1-Like-1 (NPC1L1) – Function & Importance

Niemann-Pick-C1-Like-1 (NPC1L1) is a transport protein in the small intestine that regulates the absorption of cholesterol and phytosterols from food and serves as the molecular target of the cholesterol-lowering drug ezetimibe.

Regular tips about health Regular tips about health

Things worth knowing about "Niemann-Pick-C1-Like-1"

Niemann-Pick-C1-Like-1 (NPC1L1) is a transport protein in the small intestine that regulates the absorption of cholesterol and phytosterols from food and serves as the molecular target of the cholesterol-lowering drug ezetimibe.

What is Niemann-Pick-C1-Like-1?

Niemann-Pick-C1-Like-1 (NPC1L1) is a membrane-bound transport protein expressed primarily in the enterocytes (intestinal epithelial cells) of the small intestine, with lower expression levels in the liver. It plays a central role in the intestinal absorption of dietary cholesterol and plant-derived sterols (phytosterols). Its name derives from its structural similarity to the Niemann-Pick C1 protein (NPC1), which is involved in intracellular lipid trafficking.

Mechanism of Action

NPC1L1 is an integral membrane protein with 13 transmembrane domains and belongs to the RND transporter family (Resistance-Nodulation-Division). It is located on the apical (luminal) surface of small intestinal cells and in intracellular vesicles.

The transport mechanism proceeds in several steps:

Cholesterol from the intestinal lumen binds to the NPC1L1-rich membrane region, specifically its sterol-sensing domain.
NPC1L1 internalizes cholesterol via clathrin-mediated endocytosis into the enterocytes.
The absorbed cholesterol is then packaged into chylomicrons and transported via the lymphatic system into the bloodstream.

In addition to cholesterol, NPC1L1 also transports phytosterols (e.g., sitosterol, campesterol) and, to a lesser extent, vitamin E (tocopherols) and other fat-soluble compounds.

Role in Cholesterol Metabolism

The human body absorbs approximately 200–400 mg of dietary cholesterol per day. NPC1L1 is the primary mediator of this intestinal cholesterol absorption. It also participates in the reabsorption of biliary cholesterol (secreted in bile) within the small intestine.

Overactivity or increased expression of NPC1L1 can lead to elevated LDL cholesterol levels in the blood and is therefore a risk factor for atherosclerosis and cardiovascular disease.

NPC1L1 as a Pharmacological Target

NPC1L1 is the molecular target of the lipid-lowering agent ezetimibe. Ezetimibe selectively binds to NPC1L1 and thereby inhibits the uptake of cholesterol from the intestinal lumen into enterocytes. This results in:

A reduction in intestinal cholesterol absorption by up to 50 %
A decrease in plasma LDL cholesterol by approximately 15–20 %
A complementary effect to statins when used in combination therapy

Ezetimibe is used in patients with hypercholesterolemia, particularly when statins alone are insufficient or not tolerated.

Genetic Variants and Clinical Relevance

Certain genetic polymorphisms (gene variants) in the NPC1L1 gene can influence the rate of cholesterol absorption. Carriers of loss-of-function mutations in the NPC1L1 gene naturally exhibit reduced cholesterol absorption and have a significantly lower risk of coronary heart disease. This finding supports the causal role of NPC1L1 in cardiovascular risk and provides the rationale for ezetimibe as a therapeutic option.

NPC1L1 is also expressed in the liver, where it may be involved in the reabsorption of biliary cholesterol from bile, although the clinical significance of this hepatic expression in humans has not yet been fully elucidated.

Summary

NPC1L1 is an essential transport protein for cholesterol uptake in the small intestine. Its pharmacological inhibition by ezetimibe is an established therapeutic approach for lowering LDL cholesterol and reducing cardiovascular risk. Genetic studies confirm its central importance for lipid metabolism in humans.

References

Altmann, S.W. et al. (2004): Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 303(5661), 1201–1204.
Davis, H.R. & Altmann, S.W. (2009): Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochimica et Biophysica Acta, 1791(7), 679–683.
Cannon, C.P. et al. (2015): Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 372(25), 2387–2397.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.